Table 1.
Characteristics of the patients in BFB+ and in BFB−.
| BFB+ | BFB− | p | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Median | Range | Mean | SD | Median | Range | ||
| Age (y.o) | 46.12 | 2.04 | 49 | 24–77 | 56.82 | 1.34 | 58 | 23–82 | 0.0535 |
| BMI | 24.16 | 0.64 | 21.78 | 19.63–35.16 | 25.47 | 0.35 | 25.95 | 18.75–29.97 | 0.04463 |
| TFU | 2321.05 | 16.47 | 2200 | 1650–4380 | 2392.97 | 10.56 | 2098 | 1247–5720 | 0.8502 |
| YPT | 3.2 | 0.17 | 2.5 | 1–6 | 6.58 | 0.49 | 5 | 1–20 | 0.0391 |
| SF-36 basal | 42.98 | 2.44 | 42.00 | 41–47 | 47.96 | 6.17 | 45.00 | 40–58 | 0.0046 |
| Concurrent diseases or conditions | |||||||||
| BFB− (n = 75) n = 48 |
BFB+ (n = 48) n = 75 |
p | |||||||
| n | % | n | % | ||||||
| HT | 0 | 0.00 | 5 | 6.67 | 0.1553 | ||||
| DM | 0 | 0.00 | 3 | 4.00 | 0.2803 | ||||
| Hypothyroidism | 10 | 20.83 | 0 | 0.00 | 0.0001 | ||||
| Depression | 6 | 12.50 | 6 | 8.00 | 0.5355 | ||||
| Other pathological conditions or diseases | 32 | 66.67 | 45 | 60.00 | 0.5677 | ||||
| More than 2 concurrent medical conditions | 6 | 12.50 | 1 | 1.33 | 0.0140 | ||||
| History of UTI | 0 | 0.00 | 1 | 1.33 | 1.0000 | ||||
| Overactive bladder | 5 | 10.42 | 2 | 2.67 | 0.1088 | ||||
| UI | 0 | 0.00 | 1 | 1.33 | 1.0000 | ||||
| Mild or level 1 urinary incontinence | 0 | 0.00 | 4 | 5.33 | 0.1553 | ||||
| Non-repaired cystocele | 0 | 0.00 | 2 | 2.67 | 0.5202 | ||||
| Non-repaired rectocele | 0 | 0.00 | 1 | 1.33 | 1.0000 | ||||
| Concurrent treatment with benzodiazepine | 19 | 39.58 | 9 | 12.00 | 0.0007 | ||||
| Concurrent treatment with anticholinergics | 0 | 0.00 | 9 | 12.00 | 0.0118 | ||||
| Concurrent treatment with topical oestrogens | 10 | 20.83 | 3 | 4.00 | 0.0052 | ||||
| Concurrent treatment with second-step analgesic drugs | 0 | 0.00 | 3 | 4.00 | 0.2803 | ||||
| Concurrent treatment with third-step analgesic drugs | 19 | 39.58 | 11 | 14.67 | 0.0024 | ||||
| Concurrent treatment with amitriptyline antidepressant | 14 | 29.17 | 15 | 20.00 | 0.2797 | ||||
| Treatment with intravesical instillation of GAG | 26 | 54.17 | 25 | 33.33 | 0.0256 | ||||
| Other pharmacological treatments | 24 | 50.00 | 27 | 36.00 | 0.1373 | ||||
| More than 2 concurrent treatments | 19 | 39.58 | 26 | 34.67 | 0.7014 | ||||
| Smoker | 5 | 10.42 | 10 | 13.33 | 0.7802 | ||||
| Toxic habit plus concurrent medical conditions | 5 | 10.42 | 0 | 0.00 | 0.0079 | ||||
| Surgical Background | |||||||||
| UI surgery | 10 | 20.83 | 8 | 10.67 | 0.1898 | ||||
| Repaired cystocele | 6 | 12.50 | 8 | 10.67 | 0.7771 | ||||
| Curettage | 0 | 0.00 | 2 | 2.67 | 0.5202 | ||||
| Hysterectomy | 0 | 0.00 | 7 | 9.33 | 0.0419 | ||||
| Other surgical interventions | 17 | 35.42 | 17 | 22.67 | 0.1495 | ||||
| Gynecological cancer surgery | 0 | 0.00 | 1 | 1.33 | 1.0000 | ||||
| History of more than 2 concurrent surgical interventions | 11 | 22.92 | 11 | 14.67 | 0.3348 | ||||
| Toxic habit plus history of concurrent surgical interventions | 0 | 0.00 | 2 | 2.67 | 0.5202 | ||||
| Obstetric Background | |||||||||
| Cesarean section | 0 | 0.00 | 2 | 2.67 | 0.5202 | ||||
| Eutocic delivery | 0 | 0.00 | 12 | 16.00 | 0.0032 | ||||
| Dystocic delivery | 10 | 20.83 | 1 | 1.33 | 0.0003 | ||||
BMI: body mass index; BFB+: group of patients who received adjuvant biofeedback (BFB) of the pelvic floor; BFB−: group of patients who did not received biofeedback of the pelvic floor; TFU: total time of follow-up; y.o.: years old; YPT: years of BPS/IC prior to starting the treatment.